keyword
https://read.qxmd.com/read/38502227/brentuximab-vedotin-and-chemotherapy-in-relapsed-refractory-hodgkin-lymphoma-a-propensity-score-matched-analysis
#21
JOURNAL ARTICLE
Julia Driessen, Fer de Wit, Alex F Herrera, Pier Luigi Zinzani, Ann S LaCasce, Peter D Cole, Craig H Moskowitz, Ramón García-Sanz, Michael Fuchs, Horst Mueller, Peter Borchmann, Armando Santoro, Heiko Schöder, Josée M Zijlstra, Barbara A Hutten, Alison J Moskowitz, Marie José Kersten
Several single-arm studies have explored the inclusion of brentuximab vedotin (BV) in salvage chemotherapy followed by autologous stem-cell transplantation (ASCT) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, no head-to-head comparisons with standard salvage chemotherapy have been performed. This study presents a propensity score-matched analysis encompassing individual patient data from ten clinical trials to evaluate the impact of BV in transplant-eligible R/R cHL patients. We included 768 patients, of whom 386 were treated with BV +/- chemotherapy (BV-cohort), while 382 received chemotherapy alone (chemo-cohort)...
March 19, 2024: Blood Advances
https://read.qxmd.com/read/38500657/intracranial-non-germinomatous-germ-cell-tumors-in-children-and-adolescents-how-can-the-experience-from-an-uppermiddle-income-country-contribute-to-the-worldwide-effort-to-improve-outcomes
#22
JOURNAL ARTICLE
Andrea M Cappellano, Natalia Dassi, Bruna M Mançano, Sidnei Epelman, Daniela B Almeida, Sergio Cavalheiro, Patricia A Dastoli, Maria T S Alves, Jardel M Nicacio, Marcos D S Costa, Frederico A Silva, Simone S Aguiar, Maria L Figueiredo, Michael Chen, Nasjla S Silva, Jonathan L Finlay
BACKGROUND: Non-germinomatous germ cell tumors (NGGCT) accounts for one third of intracranial GCT. While the germinoma group have an excellent overall survival, the standard of practice for children with NGGCT is still under evaluation. AIMS: Describe the results of the of the Brazilian consortium protocol. METHODS: Since 2013, 15 patients with a diagnosis of NGGCT by histopathology and/or serum/cerebrospinal fluid (CSF) tumor markers, βHCG >200mlU/ml and/or positive alpha-fetoprotein were treated with neoadjuvant chemotherapy with carboplatin, cyclophosphamide and etoposide followed by ventricular radiotherapy (RTV) of 18Gy with boost (32Gy) to the primary site...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38499538/progression-free-survival-of-myeloma-patients-who-become-ife-negative-correlates-with-the-detection-of-residual-monoclonal-free-light-chain-flc-by-mass-spectrometry
#23
JOURNAL ARTICLE
H V Giles, M T Drayson, B Kishore, C Pawlyn, M Kaiser, G Cook, R de Tute, R G Owen, D Cairns, T Menzies, F E Davies, G J Morgan, G Pratt, G H Jackson
Deeper responses are associated with improved survival in patients being treated for myeloma. However, the sensitivity of the current blood-based assays is limited. Historical studies suggested that normalisation of the serum free light chain (FLC) ratio in patients who were negative by immunofixation electrophoresis (IFE) was associated with improved outcomes. However, recently this has been called into question. Mass spectrometry (MS)-based FLC assessments may offer a superior methodology for the detection of monoclonal FLC due to greater sensitivity...
March 18, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38498976/autologous-hsct-with-novel-agent-based-induction-and-consolidation-followed-by-lenalidomide-maintenance-for-untreated-multiple-myeloma
#24
JOURNAL ARTICLE
Yasuo Mori, Jun Takizawa, Yuna Katsuoka, Naoki Takezako, Koji Nagafuji, Hiroshi Handa, Junya Kuroda, Kazutaka Sunami, Tomohiko Kamimura, Ryosuke Ogawa, Yoshikane Kikushige, Mine Harada, Koichi Akashi, Toshihiro Miyamoto
Triplet regimen comprising proteasome inhibitors, immunomodulatory drugs, and dexamethasone (DEX) is a recommended induction/consolidation therapy for multiple myeloma (MM) patients eligible for transplant. In this Japanese phase II study conducted from 2017 to 2019, newly diagnosed MM patients aged 20-65 received four induction cycles with bortezomib (Bor), lenalidomide (Len), and DEX (VRD), followed by Bor and high-dose melphalan with autologous stem cell rescue. Subsequently, they underwent four consolidation cycles with carfilzomib, Len, and DEX (KRD), followed by Len maintenance until disease progression...
March 18, 2024: Cancer Science
https://read.qxmd.com/read/38498174/frontline-treatment-of-mantle-cell-lymphoma
#25
JOURNAL ARTICLE
Christine E Ryan, Philippe Armand, Ann S LaCasce
Despite many recent therapeutic advances, mantle cell lymphoma (MCL) remains a largely incurable disease. Treatments for patients with relapsed/refractory (R/R) disease are limited in number and in response durability. Therefore, improving the efficacy of frontline (1L) treatment, and specifically maximizing the duration of first remission, remains of critical importance to obtain favorable long-term outcomes. As 1L treatments become more effective, improving tolerability is also becoming an increasingly realistic goal...
March 18, 2024: Blood
https://read.qxmd.com/read/38496600/combining-cell-intrinsic-and-extrinsic-resistance-to-hiv-1-by-engineering-hematopoietic-stem-cells-for-ccr5-knockout-and-b-cell-secretion-of-therapeutic-antibodies
#26
William N Feist, Sofia E Luna, Kaya Ben-Efraim, Maria V Filsinger Interrante, Nelson A Amorin, Nicole M Johnston, Theodora U J Bruun, Hana Y Ghanim, Benjamin J Lesch, Amanda M Dudek, Matthew H Porteus
Autologous transplantation of CCR5 null hematopoietic stem and progenitor cells (HSPCs) is the only known cure for HIV-1 infection. However, this treatment is limited because of the rarity of CCR5 -null matched donors, the morbidities associated with allogeneic transplantation, and the prevalence of HIV-1 strains resistant to CCR5 knockout (KO) alone. Here, we propose a one-time therapy through autologous transplantation of HSPCs genetically engineered ex vivo to produce both CCR5 KO cells and long-term secretion of potent HIV-1 inhibiting antibodies from B cell progeny...
March 9, 2024: bioRxiv
https://read.qxmd.com/read/38496369/burkitt-s-lymphoma-in-a-young-boy-progressing-to-systemic-lupus-erythematosus-during-follow-up-a-case-report-and-literature-review
#27
Chenxi Liu, Ci Pan, Yingying Jin, Hua Huang, Fei Ding, Xuemei Xu, Shengfang Bao, Xiqiong Han, Yanliang Jin
INTRODUCTION: Patients with systemic lupus erythematosus (SLE) are at a higher risk of developing cancer, particularly hematological malignancies such as lymphoma and leukemia. However, existing studies on this topic that assess cancer incidence following SLE diagnosis are limited. In addition, SLE can be diagnosed after cancer, although such cases in children have been rarely reported. CASE REPORT: We present the case of a 2.6-year-old boy who presented to our institute with fever and abdominal pain...
2024: Frontiers in Pediatrics
https://read.qxmd.com/read/38494543/matching-adjusted-indirect-comparison-of-brexucabtagene-autoleucel-zuma-2-and-pirtobrutinib-bruin-in-patients-with-relapsed-refractory-mantle-cell-lymphoma-previously-treated-with-a-covalent-bruton-tyrosine-kinase%C3%A2-inhibitor
#28
JOURNAL ARTICLE
Gilles Salles, Jenny M H Chen, Ina Zhang, Fabio Kerbauy, James J Wu, Sally W Wade, Ana Nunes, Chaoling Feng, Ioana Kloos, Weimin Peng, Julia T Snider, Dylan Maciel, Keith Chan, Sam Keeping, Bijal Shah
INTRODUCTION: Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) often require multiple lines of treatment and have a poor prognosis, particularly after failing covalent Bruton tyrosine kinase inhibitor (cBTKi) therapy. Newer treatments such as brexucabtagene autoleucel (brexu-cel, chimeric antigen receptor T cell therapy) and pirtobrutinib (non-covalent BTKi) show promise in improving outcomes. METHODS: Without direct comparative evidence, an unanchored matching-adjusted indirect comparison was conducted to estimate the relative treatment effects of brexu-cel and pirtobrutinib for post-cBTKi R/R MCL...
March 18, 2024: Advances in Therapy
https://read.qxmd.com/read/38494399/the-use-of-a-high-flow-picc-catheter-for-stem-cell-and-lymphocyte-apheresis-the-initial-experience-of-a-pediatric-oncology-center-in-brazil
#29
JOURNAL ARTICLE
Vilani Kremer, Andréia Rheinheimer, Ana Luiza Rodrigues, Andressa Taborda, Robson Coelho, Antonella Zanette
BACKGROUND: Autologous hematopoietic stem cell transplant (HSCT), characterized by high intensity chemotherapy followed by the infusion of HSC previously collected from the peripheral blood, is a procedure used in the treatment of several malignancies. In pediatrics, the apheresis procedure represents a challenge, due to the need for insertion of a rigid central venous catheter (CVC) in small children. The CVC is usually used for stem cell collection and then removed. Later, the patient will need a new device for cell infusion...
February 24, 2024: Journal of Pediatric Surgery
https://read.qxmd.com/read/38493059/soho-state-of-the-art-updates-and-next-questions-treatment-evolution-of-mantle-cell-lymphoma-navigating-the-different-entities-and-biological-heterogeneity-of-mantle-cell-lymphoma-in-2024
#30
REVIEW
Andrew Ip, Alexandra Della Pia, Andre H Goy
Progress in mantle cell lymphoma (MCL) has led to significant improvement in outcomes of patients even in the real world (RW) setting albeit to a lesser degree. In parallel to the demonstration of benefit using combination therapy with rituximab plus high-dose cytarabine (R-AraC) as well as dose intensive therapy-autologous stem cell transplantation (DIT-ASCT) consolidation and maintenance, it became clear over the last 2 decades that MCL is a highly heterogenous disease at the molecular level, explaining differences observed in clinical behavior and response to therapy...
February 22, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38493007/revolutionising-healing-gene-editing-s-breakthrough-against-sickle-cell-disease
#31
REVIEW
Marija Dimitrievska, Dravie Bansal, Marta Vitale, John Strouboulis, Annarita Miccio, Kypros H Nicolaides, Sara El Hoss, Panicos Shangaris, Joanna Jacków-Malinowska
Recent advancements in gene editing illuminate new potential therapeutic approaches for Sickle Cell Disease (SCD), a debilitating monogenic disorder caused by a point mutation in the β-globin gene. Despite the availability of several FDA-approved medications for symptomatic relief, allogeneic hematopoietic stem cell transplantation (HSCT) remains the sole curative option, underscoring a persistent need for novel treatments. This review delves into the growing field of gene editing, particularly the extensive research focused on curing haemoglobinopathies like SCD...
March 7, 2024: Blood Reviews
https://read.qxmd.com/read/38486828/autologous-hematopoietic-stem-cell-transplant-at-a-tertiary-care-centre-in-india-achieving-comparable-outcomes-with-adaptations
#32
JOURNAL ARTICLE
Aditya Kumar Gupta, Jagdish Prasad Meena, Rachna Seth, Priyanka Naranje, Sujata Mohanty, Poonam Coshic
Autologous stem cell transplantation (ASCT) is the standard treatment for many high-risk solid tumors. Patients undergoing ASCT should be managed in a dedicated hematopoietic stem cell transplantation (HSCT) unit with isolation rooms, high-efficiency particulate air (HEPA) filters, and positive pressure. We report the outcomes of the first 20 pediatric patients who underwent ASCT in isolation rooms with no HEPA filters or positive pressure. Moreover, the isolation rooms were not part of a dedicated HSCT unit...
February 25, 2024: Blood Cell Ther
https://read.qxmd.com/read/38485549/outcomes-of-upfront-plerixafor-use-for-mobilization-in-germ-cell-tumor-patients
#33
JOURNAL ARTICLE
Jaimie Cohen, Shreya Shah, Katrina Piedra, Sila Shalhoub, Cara Benjamin, Denise Pereira
High-dose chemotherapy with autologous hematopoietic stem cell transplantation (auto-HSCT) improved 5-year overall survival rates in relapsed/refractory germ cell tumors (GCTs) from 10% to 52%. Nearly 30% of GCT patients are deemed poor mobilizers after receiving several lines of prior therapy. There is limited data available regarding upfront plerixafor use in GCT patients. We predicted upfront plerixafor use would increase the amount of stem cells collected preventing subsequent mobilizations and improve time to curative therapy...
March 4, 2024: Hematology, Transfusion and Cell Therapy
https://read.qxmd.com/read/38484479/from-the-archives-of-md-anderson-cancer-center-monomorphic-epitheliotropic-intestinal-t-cell-lymphoma-a-case-with-an-unusual-immunophenotype-and-discussion-of-differential-diagnosis
#34
REVIEW
Nicholas J Dcunha, Qing Wei, Beenu Thakral, L Jeffrey Medeiros
Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare and aggressive T-cell neoplasm associated with poor survival. We report a case of MEITL that presented as an ulcerated mass in the jejunum with perforation. Microscopic examination showed that the neoplasm involved the full thickness of the intestinal wall, extended into the mesentery, and was composed of monomorphic, small to medium-size cells. Immunohistochemical analysis showed that the neoplastic cells were positive for T-cell receptor (TCR) delta, CD3, CD7, CD8 (small subset), BCL-2 and TIA-1, and negative for TCR beta, CD4, CD5, CD10, CD20, CD30, CD34, CD56, CD57, CD99, ALK, cyclin D1, granzyme B, MUM1/IRF4, and TdT...
March 8, 2024: Annals of Diagnostic Pathology
https://read.qxmd.com/read/38483359/good-manufacturing-practice-compliant-human-induced-pluripotent-stem-cells-from-bench-to-putative-clinical-products
#35
JOURNAL ARTICLE
Juan J Novoa, Inge M Westra, Esther Steeneveld, Natascha Fonseca Neves, Christiaan H Arendzen, Bahareh Rajaei, Esmée Grundeken, Mehmet Yildiz, Wouter van der Valk, Alison Salvador, Françoise Carlotti, Pascale F Dijkers, Heiko Locher, Cathelijne W van den Berg, Karine I Raymond, Agnete Kirkeby, Christine L Mummery, Ton J Rabelink, Christian Freund, Pauline Meij, Brigitte Wieles
BACKGROUND AIMS: Few human induced pluripotent stem cell (hiPSC) lines are Good Manufacturing Practice (GMP)-compliant, limiting the clinical use of hiPSC-derived products. Here, we addressed this by establishing and validating an in-house platform to produce GMP-compliant hiPSCs that would be appropriate for producing both allogeneic and autologous hiPSC-derived products. METHODS: Our standard research protocol for hiPSCs production was adapted and translated into a GMP-compliant platform...
March 5, 2024: Cytotherapy
https://read.qxmd.com/read/38481949/progress-and-prospect-of-asct-combined-with-car-t-therapy-in-the-treatment-of-multiple-myeloma
#36
REVIEW
Shihui Yuan, Ying Chen, Huasheng Liu
Multiple myeloma (MM) is a hematological cancer characterized by abnormal proliferation of plasma cells in bone marrow. In recent years, autologous stem cell transplantation (ASCT) has become the cornerstone of MM treatment. At the same time, immunotherapy, such as monoclonal antibody therapy and chimeric antigen receptor T cell (CAR-T) has also emerged, in which CAR-T is the most attractive focus. ASCT and its myeloablative preconditioning will turn its immune microenvironment into an inhibited state, which may provide an opportunity for the expansion of CAR-T cells so as to further clear the residual lesions after ASCT and reduce the recurrence rate after ASCT...
2024: Therapeutic Advances in Hematology
https://read.qxmd.com/read/38478225/soft-tissue-reconstruction
#37
JOURNAL ARTICLE
Mario Alessandri-Bonetti, Francesco M Egro, Kacey G Marra
Autologous fat transplantation has revolutionized soft tissue reconstruction, but conventional methods remain unpredictable as graft resorption rates are high due to lack of vascularization. The advent of adipose-derived stem cells (ASCs) has led to improvement of fat grafting outcomes, in part to their ability to undergo facile differentiation into adipose tissue, their angiogenic properties, and their ability to express and secrete multiple growth factors. This chapter discusses the isolation and characterization of human ASCs, its expansion in vitro, and relevant in vivo models for adipose tissue engineering...
2024: Methods in Molecular Biology
https://read.qxmd.com/read/38477039/review-of-advanced-practice-nurse-role-in-infection-throughout-the-hematopoietic-stem-cell-transplant-journey
#38
REVIEW
Maddie Gilsenan, Sam Van Der Linde, Geoff Hill, Belinda Lambros
BACKGROUND: Prolonged periods of immunosuppression during hematopoietic stem cell transplant (HSCT) can result in serious infectious complications and contribute to transplant-related morbidity and mortality. Adherence to standardized pre and postinfection screening guidelines, prescribed medications, and early identification of infectious symptoms through comprehensive patient and family education are crucial to minimizing infectious complications. Advanced practice nurses (APNs) are key members of the multidisciplinary care team in the HSCT specialty, maintaining a specialized skillset and scope of practice which includes a holistic based, preventative medicine and risk mitigation approach...
March 13, 2024: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://read.qxmd.com/read/38473382/ixazomib-lenalidomide-and-dexamethasone-ird-treatment-with-cytogenetic-risk-based-maintenance-in-transplant-eligible-myeloma-a-phase-2-multicenter-study-by-the-nordic-myeloma-study-group
#39
JOURNAL ARTICLE
Anu Partanen, Anders Waage, Valdas Peceliunas, Fredrik Schjesvold, Pekka Anttila, Marjaana Säily, Katarina Uttervall, Mervi Putkonen, Kristina Carlson, Einar Haukas, Marja Sankelo, Damian Szatkowski, Markus Hansson, Anu Marttila, Ronald Svensson, Per Axelsson, Birgitta Lauri, Maija Mikkola, Conny Karlsson, Johanna Abelsson, Erik Ahlstrand, Anu Sikiö, Monika Klimkowska, Reda Matuzeviciene, Mona Hoysaeter Fenstad, Sorella Ilveskero, Tarja-Terttu Pelliniemi, Hareth Nahi, Raija Silvennoinen
Scarce data exist on double maintenance in transplant-eligible high-risk (HR) newly diagnosed multiple myeloma (NDMM) patients. This prospective phase 2 study enrolled 120 transplant-eligible NDMM patients. The treatment consisted of four cycles of ixazomib-lenalidomide-dexamethasone (IRD) induction plus autologous stem cell transplantation followed by IRD consolidation and cytogenetic risk-based maintenance therapy with lenalidomide + ixazomib (IR) for HR patients and lenalidomide (R) alone for NHR patients...
February 29, 2024: Cancers
https://read.qxmd.com/read/38472362/risk-factors-of-early-disease-progression-and-decreased-survival-for-multiple-myeloma-patients-after-upfront-autologous-stem-cell-transplantation
#40
JOURNAL ARTICLE
Te-Lin Hsu, Chun-Kuang Tsai, Chun-Yu Liu, Chiu-Mei Yeh, Fen-Lan Lin, Liang-Tsai Hsiao, Yao-Chung Liu, Sheng-Hsuan Chien, Hao-Yuan Wang, Po-Shen Ko, Ting-An Lin, Wen-Chun Chen, Po-Min Chen, Jin-Hwang Liu, Jyh-Pyng Gau, Chia-Jen Liu
Multiple myeloma (MM) stands as the second most prevalent hematological malignancy, constituting approximately 10% of all hematological malignancies. Current guidelines recommend upfront autologous stem cell transplantation (ASCT) for transplant-eligible MM patients. This study seeks to delineate factors influencing post-ASCT outcomes in MM patients. Our cohort comprised 150 MM patients from Taipei Veterans General Hospital, with progression-free survival (PFS) as the primary endpoint and overall survival (OS) as the secondary endpoint...
March 13, 2024: Annals of Hematology
keyword
keyword
11335
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.